Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RADIANCE Part B: Ozanimod vs Interferon beta-1a in Relapsing MS
NCT02047734Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Dec 2013
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 21
01
Overview
A Phase 3 trial of ozanimod in multiple sclerosis (MS), sponsored by Celgene Corporation. Started Dec 2013; status: completed.
02
Drugs
ozanimod
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NCT02047734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02047734.